Nektar Therapeutics stock gains 2.98 percent on trial watch

Published on 09/24/2026 at 22:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nektar Therapeutics stock reached USD 59.38 on September 24, 2026, after rising from USD 57.66. Q2 revenue was USD 10.1 million and cash reached USD 1.02 billion.

Nektar Therapeutics, biotechnology, REZOLVE-AA, clinical data, Nasdaq, Illustration mit AI erstellt.

Nektar Therapeutics (ISIN US6402681083) stock was trading at USD 59.38 on Nasdaq on September 24, 2026, up 2.98 percent from USD 57.66. The move comes as the company approaches a clinical data checkpoint after entering a quiet period for its REZOLVE-AA study.

REZOLVE-AA data set the next checkpoint

According to StockTitan, Nektar began the quiet period on September 8, 2026, ahead of data from the 24-week off-treatment follow-up in the Phase 2b REZOLVE-AA trial of rezpegaldesleukin.

The study concerns patients with severe-to-very-severe alopecia areata, making the upcoming readout a direct test of durability after treatment. Nektar is also advancing rezpegaldesleukin in Phase 3 development for atopic dermatitis, according to the company release dated August 25, 2026.

Cash supports the clinical program

Second-quarter 2026 non-cash royalty revenue totaled USD 10.1 million, while net loss reached USD 40.6 million, or USD 1.23 per share, according to Yahoo Finance. The revenue figure gives the stock a relatively clear valuation tension: the company is carrying a large cash balance while funding a loss-making clinical pipeline.

Nektar ended Q2 2026 with USD 1.02 billion in cash and investments and no debt. That balance is a central support for the development plan, but the next material valuation test remains clinical rather than commercial because the lead programs are still in development.

Stock remains below its yearly high

Nektar Therapeutics stock has a 52-week range of USD 33.40 to USD 109.00 as of September 24, 2026. Its market capitalization was USD 1,703,491,243 on the same date, putting the latest price 45.62 percent below the 52-week high.

At USD 59.38 on Nasdaq on September 24, 2026, the stock was higher than the prior close of USD 57.66. The next REZOLVE-AA data update therefore matters because it can add clinical evidence to a share price that remains well below its yearly peak.